Co-delivery of the NKT agonist -galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses

Ghinnagow, R.; Meester, J. de; Cruz, L.J.; Aspord, C.; Corgnac, S.; Macho-Fernandez, E.; ... ; Trottein, F. (2017)

Article / Letter to editor

• Cancer
• dendritic cells
• natural killer T cells
• self antigens
• targeting
• vaccine

• All authors: Ghinnagow, R.; Meester, J. de; Cruz, L.J.; Aspord, C.; Corgnac, S.; Macho-Fernandez, E.; Soulard, D.; Fontaine, J.; Chaperot, L.; Charles, J.; Soncin, F.; Mami-Chouaib, F.; Plumas, J.; Faveeuw, C.; Trottein, F.
• Date: 2017-12-31
• Journal: OncoImmunology
• Volume: 6
• Issue: 9
• DOI: doi:10.1080/2162402X.2017.1339855